Rieger Jayson 4

4 · Verrica Pharmaceuticals Inc. · Filed Nov 26, 2024

Form 4

Period: 2024-11-22

DirectorCEO and President

Transactions

Purchase
Series B Warrants (right to buy)
2024-11-22+140,449→ 140,449 total
Exercise: $1.33From: 2024-11-22Exp: 2029-11-22→ Common Stock (140,449 underlying)
Gift
Common Stock
2024-11-26+50,000→ 882,826 total
Purchase
Common Stock
2024-11-22+280,898→ 832,826 total
Purchase
Series A Warrants (right to buy)
2024-11-22+140,449→ 140,449 total
Exercise: $1.07From: 2024-11-22Exp: 2025-11-22→ Common Stock (140,449 underlying)

Holdings

Footnotes (2)

[F1]The reported securities are included within 280,898 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.
[F2]These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person is a co-trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Documents

1 file